Search

Your search keyword '"Raida, Ludek"' showing total 49 results
Start Over Author "Raida, Ludek"
49 results on '"Raida, Ludek"'

1. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

Author

Hernández-Boluda, Juan Carlos, Eikema, Diderik-Jan, Koster, Linda, Kröger, Nicolaus, Robin, Marie, de Witte, Moniek, Finke, Jürgen, Finazzi, Maria Chiara, Broers, Annoek, Raida, Ludek, Schaap, Nicolaas, Chiusolo, Patrizia, Verbeek, Mareike, Hazenberg, Carin L. E., Halaburda, Kazimierz, Kulagin, Aleksandr, Labussière-Wallet, Hélène, Gedde-Dahl, Tobias, Rabitsch, Werner, Raj, Kavita, Drozd-Sokolowska, Joanna, Battipaglia, Giorgia, Polverelli, Nicola, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and McLornan, Donal P.

Published
2023
Full Text
View/download PDF

3. Pneumocystis Pneumonia After Allogeneic Hematopoietic Cell Transplantation: A Case-Control Study on Epidemiology and Risk Factors on Behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Robin, Christine, Cordonnier, Catherine, Tridello, Gloria, Knelange, Nina, Xhaard, Alienor, Chantepie, Sylvain, Tanguy-Schmidt, Aline, Schouten, Harry C., Yeshurun, Moshe, Rocha, Vanderson, Srour, Micha, Kröger, Nicolaus, Ledoux, Marie-Pierre, Dalgaard, Jakob, Thiebaut, Anne, Giardino, Stefano, Calore, Elisabetta, Zuckerman, Tsila, Groll, Andreas H., Raida, Ludek, Avcin, Simona, Vicent, Marta Gonzalez, Kaare, Ain, Drozd-Sokolowska, Joanna, Turlure, Pascal, Bretagne, Stéphane, Mikulska, Malgorzata, Camara, Rafael de la, Cesaro, Simone, and Styczynski, Jan

Published
2024
Full Text
View/download PDF

7. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study

Author

Penack, Olaf, primary, Luft, Thomas, additional, Peczynski, Christophe, additional, Benner, Axel, additional, Sica, Simona, additional, Arat, Mutlu, additional, Itäla-Remes, Maija, additional, Corral, Lucia López, additional, Schaap, Nicolaas P M, additional, Karas, Michal, additional, Raida, Ludek, additional, Schroeder, Thomas, additional, Dreger, Peter, additional, Metafuni, Elisabetta, additional, Ozcelik, Tulay, additional, Sandmaier, Brenda M, additional, Kordelas, Lambros, additional, Moiseev, Ivan, additional, Schoemans, Hélène, additional, Koenecke, Christian, additional, Basak, Grzegorz W, additional, and Peric, Zinaida, additional

Published
2024
Full Text
View/download PDF

8. Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Robin, Christine, primary, Cordonnier, Catherine, additional, Tridello, Gloria, additional, Knelange, Nina, additional, Xhaard, Alienor, additional, Chantepie, Sylvain, additional, Tanguy-Schmidt, Aline, additional, Schouten, Harry C, additional, Yesherun, Moshe, additional, Rocha, Vanderson, additional, Srour, Micha, additional, Kröger, Nicolaus, additional, Ledoux, Marie-Pierre, additional, Dalgaard, Jakob, additional, Thiebaut, Anne, additional, Giardino, Stefano, additional, Calore, Elisabetta, additional, Zuckerman, Tsila, additional, Groll, Andreas H, additional, Raida, Ludek, additional, Avcin, Simona, additional, Vicent, Marta Gonzalez, additional, Kaare, Ain, additional, Drozd-Sokolowska, Joanna, additional, Turlure, Pascal, additional, Bretagne, Stéphane, additional, Mikulska, Malgorzata, additional, Camara, Rafael de la, additional, Cesaro, Simone, additional, and Styczynski, Jan, additional

Published
2023
Full Text
View/download PDF

9. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT

Author

van Gelder, Michel, Ziagkos, Dimitris, de Wreede, Liesbeth, van Biezen, Anja, Dreger, Peter, Gramatzki, Martin, Stelljes, Matthias, Andersen, Niels Smedegaard, Schaap, Nicolaas, Vitek, Antonin, Beelen, Dietrich, Lindström, Vesa, Finke, Jürgen, Passweg, Jacob, Eder, Matthias, Machaczka, Maciej, Delgado, Julio, Krüger, William, Raida, Luděk, Socié, Gerard, Jindra, Pavel, Afanasyev, Boris, Wagner, Eva, Chalandon, Yves, Henseler, Anja, Schoenland, Stefan, Kröger, Nicolaus, and Schetelig, Johannes

Published
2017
Full Text
View/download PDF

10. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

Author

CTI De Witte, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Hernández-Boluda, Juan Carlos, Eikema, Diderik-Jan, Koster, Linda, Kröger, Nicolaus, Robin, Marie, de Witte, Moniek, Finke, Jürgen, Finazzi, Maria Chiara, Broers, Annoek, Raida, Ludek, Schaap, Nicolaas, Chiusolo, Patrizia, Verbeek, Mareike, Hazenberg, Carin L E, Halaburda, Kazimierz, Kulagin, Aleksandr, Labussière-Wallet, Hélène, Gedde-Dahl, Tobias, Rabitsch, Werner, Raj, Kavita, Drozd-Sokolowska, Joanna, Battipaglia, Giorgia, Polverelli, Nicola, Czerw, Tomasz, Yakoub-Agha, Ibrahim, McLornan, Donal P, CTI De Witte, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Hernández-Boluda, Juan Carlos, Eikema, Diderik-Jan, Koster, Linda, Kröger, Nicolaus, Robin, Marie, de Witte, Moniek, Finke, Jürgen, Finazzi, Maria Chiara, Broers, Annoek, Raida, Ludek, Schaap, Nicolaas, Chiusolo, Patrizia, Verbeek, Mareike, Hazenberg, Carin L E, Halaburda, Kazimierz, Kulagin, Aleksandr, Labussière-Wallet, Hélène, Gedde-Dahl, Tobias, Rabitsch, Werner, Raj, Kavita, Drozd-Sokolowska, Joanna, Battipaglia, Giorgia, Polverelli, Nicola, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and McLornan, Donal P

Published
2023

12. Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis

Author

Hernandez Boluda, Juan Carlos, primary, Eikema, Dirk-Jan, additional, Erazo, Nadia, additional, Kröger, Nicolaus, additional, Robin, Marie, additional, de Witte, Moniek, additional, Finke, Jürgen, additional, Rambaldi, Alessandro, additional, Broers, Annoek E.C., additional, Raida, Ludek, additional, Schaap, Nicolaas, additional, Chiusolo, Patrizia, additional, Verbeek, Mareike, additional, Choi, Goda, additional, Halaburda, Kazimierz, additional, Kulagin, Alexander D., additional, Labussiere-Wallet, Helene, additional, Gedde-Dahl, Tobias, additional, Rabitsch, Werner, additional, Raj, Kavita, additional, Drozd-Sokolowska, Joanna, additional, Polverelli, Nicola, additional, Czerw, Tomasz, additional, Yakoub-Agha, Ibrahim, additional, and McLornan, Donal P., additional

Published
2022
Full Text
View/download PDF

13. p16INK4a in the Gut Mucosa Associates with NFKB1 Gene Polymorphisms and Decreased Serum Levels of Inflammation-Associated Proteins in Patients with Gastrointestinal Acute Graft Versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Author

Kuba, Adam, primary, Raida, Ludek, additional, Flodr, Patrik, additional, Mrazek, Frantisek, additional, Kriegova, Eva, additional, Papajík, Tomáš, additional, and Minarik, Jiri, additional

Published
2022
Full Text
View/download PDF

16. The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study

Author

Vokurka, Samuel, Bystrická, Eva, Svoboda, Tomáš, Škoda Gorican, Irena Katja, Sever, Matjaz, Mazur, Ewa, Kopinska, Anna, Pavlicová, Vladislava, Mocanu, Otilia, Tanase, Alina, Ghelase, Rodica, Zítková, Marie, Labudíková, Monika, Raida, Ludek, Hrabánková-Navrátilová, Darja, and Bocková, Jana

Published
2014
Full Text
View/download PDF

19. Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence

Author

Kuba, Adam and Raida, Ludek

Subjects
surgical procedures, operative, Article Subject, immune system diseases, chemical and pharmacologic phenomena
Abstract

Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). Despite a huge progress in HSCT techniques and posttransplant care, GVHD remains a significant obstacle in successful HSCT outcome. This review presents a complex summary of GVHD pathogenesis with focus on references considering basic biological processes such as DNA damage response and cellular senescence.

Published
2018
Full Text
View/download PDF

27. Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Author

Prochazka, Vit, primary, Dyskova, Tereza, additional, Prouzova, Zuzana, additional, Papajik, Tomas, additional, Minarik, Jiri, additional, Duras, Juraj, additional, Michalka, Jozef, additional, Sykorova, Alice, additional, Mikula, Peter, additional, Raida, Ludek, additional, and Kriegova, Eva, additional

Published
2015
Full Text
View/download PDF

31. The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study

Author

Vokurka, Samuel, primary, Bystrická, Eva, additional, Svoboda, Tomáš, additional, Škoda Gorican, Irena Katja, additional, Sever, Matjaz, additional, Mazur, Ewa, additional, Kopinska, Anna, additional, Pavlicová, Vladislava, additional, Mocanu, Otilia, additional, Tanase, Alina, additional, Ghelase, Rodica, additional, Zítková, Marie, additional, Labudíková, Monika, additional, Raida, Ludek, additional, Hrabánková-Navrátilová, Darja, additional, and Bocková, Jana, additional

Published
2013
Full Text
View/download PDF

33. Factors Affecting Quality of Life During and After Stem Cell Transplantation in Long Term Survivors – Comparison of Autologous and Allogeneic Stem Cell Transplantation

Author

Benesova, Katerina, primary, Trnkova, Marie, additional, Lanska, Miriam, additional, Valkova, Veronika, additional, Steinerova, Katerina, additional, Koristek, Zdenek, additional, Novak, Jan, additional, Raida, Ludek, additional, Keslova, Petra, additional, Vackova, Blanka, additional, Kruntoradova, Klara, additional, Dolezal, Tomas, additional, and Trneny, Marek, additional

Published
2012
Full Text
View/download PDF

35. COMPARISON OF NEW FLU-BU12-TG CONDITIONING WITH THE STANDARD BU-CY MYELOABLATIVE REGIMEN IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA

Author

Raida, Ludek, primary, Tucek, Pavel, additional, Faber, Edgar, additional, Vondrakova, Jana, additional, Rusinakova, Zuzana, additional, Skoumalova, Iva, additional, Hubacek, Jaromir, additional, Jarosova, Marie, additional, Katrincsakova, Beata, additional, Pikalova, Zuzana, additional, Kurfurst, Pavel, additional, and Indrak, Karel, additional

Published
2011
Full Text
View/download PDF

36. IDENTIFICATION OF E6A2 BCR-ABL FUSION IN A PHILADELPHIA-POSITIVE CML WITH MARKED BASOPHILIA: IMPLICATIONS FOR TREATMENT STRATEGY

Author

Rohon, Peter, primary, Divoka, Martina, additional, Calabkova, Lenka, additional, Mojzikova, Renata, additional, Katrincsakova, Beata, additional, Rusinakova, Zuzana, additional, Lapcikova, Anna, additional, Raida, Ludek, additional, Faber, Edgar, additional, Jarosova, Marie, additional, Divoky, Vladimir, additional, and Indrak, Karel, additional

Published
2011
Full Text
View/download PDF

38. Management of Relapsed/Refractory Hodgkin Lymphomas After ASCT in Czech Republic.

Author

Mocikova, Heidi, primary, Pytlik, Robert, additional, Raida, Ludek, additional, Zak, Pavel, additional, Markova, Jana, additional, Kral, Zdenek, additional, Steinerova, Katerina, additional, Valkova, Veronika, additional, Trnkova, Marie, additional, Vackova, Blanka, additional, Pohlreich, David, additional, Faber, Edgar, additional, Indrak, Karel, additional, Belada, David, additional, Kozak, Tomas, additional, Mayer, Jiri, additional, Vitek, Antonin, additional, Koza, Vladimir, additional, and Trneny, Marek, additional

Published
2009
Full Text
View/download PDF

39. RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION

Author

Papajik, Tomas, primary, Pikalova, Zuzana, additional, Raida, Ludek, additional, Skoumalova, Ivana, additional, Vondrakova, Jana, additional, Faber, Edgar, additional, Prochazka, Vit, additional, Kubova, Zuzana, additional, Kucerova, Ladislava, additional, Pavlik, Tomas, additional, Dusek, Ladislav, additional, and Indrak, Karel, additional

Published
2009
Full Text
View/download PDF

43. A “Single” Dose of G-CSF after Autologous Stem Cell Transplantation in Patients with Malignant Lymphoma - Third Interim Analysis of Multicentre Randomized Trial Comparing Standard Schedule with Delayed Application and Placebo.

Author

Faber, Edgar, primary, Pytlik, Robert, primary, Trneny, Marek, primary, Slaby, Jiri, primary, Kozak, Tomas, primary, Raida, Ludek, primary, Papajik, Tomas, primary, Zikesova, Eva, primary, Zapletalova, Jana, primary, Maresova, Ivana, primary, Hamouzova, Michaela, primary, and Indrak, Karel, primary

Published
2004
Full Text
View/download PDF

44. RELAPSED FOLLICULAR LYMPHOMA SEQUENTIALLY TREATED WITH RITUXIMAB AND 90Y-IBRITUMOMAB TIUXETAN. CASE REPORT.

Author

Papajik, Tomas, Prochazka, Vit, Raida, Ludek, Kubova, Zuzana, Myslivecek, Miroslav, Drymlova, Jaroslava, Buriankova, Eva, Kucerova, Ladislava, and Indrak, Karel

Abstract

Background: Monoclonal antibodies have dramatically changed the treatment possibilities for follicular lymphoma. 90Y-ibritumomab tiuxetan (Zevalin®) is the first radioimmunotherapy agent approved for the treatment of relapsed and resistant follicular lymphoma patients. Long-term benefit was observed especially for patients achieving CR after radioimmunotherapy. Methods and Results: A 65-year-old female patient with the second relapse of CD20 positive follicular lymphoma and multiple concomitant diseases was treated with four weekly doses of rituximab (375 mg/m2). 18F-fluoro-deoxyglucose positron emission tomography combined with computed tomography (PET-CT) demonstrated only partial response to therapy with persistent PET scan positivity in enlarged abdominal lymph nodes. Therefore, it was decided to treat her with a 1200-MBq (32-mCi) dose of 90Y-ibritumomab tiuxetan radioimmunotherapy. No acute complications were noted afterwards. Hematological nadirs were reached 4 weeks later, with a platelet count of 24×109/l that normalized within the next 2 weeks. The patient had neither infection nor bleeding complications. Eight weeks after radioimmunotherapy, the PET-CT scans documented only 3 lymph nodes around the abdominal aorta, maximum size 2×1 cm. The PET scan analysis proved no accumulation of 18F-fluoro-deoxy-glucose in any lymph nodes or other organs and tissues. Conclusions: Sequential treatment with rituximab and 90Y-ibritumomab tiuxetan may be an interesting alternative in cases of relapsed follicular or other indolent lymphomas in pretreated or older patients with other concomitant diseases. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

46. Allogeneic hematopoietic stem cell transplantation using HLA-compatible donors in younger high cytogenetic risk CLL patients results in very high long-term progression-free survival and may therefore favorably compete with sequential targeted therapy

Author

Gelder, Michel, Ziagkos, Dimitris, Wreede, Liesbeth, Biezen, Anja, Dreger, Peter, Gramatzki, Martin, Stelljes, Matthias, Andersen, Niels Smedegaard, Nicolaas Schaap, Vitek, Antonin, Beelen, Dietrich, Volin, Liisa, Finke, Juergen, Passweg, Jacob, Eder, Matthias, Machaczka, Maciej, Delgado, Julio, Krueger, William, Raida, Ludek, Socie, Gerard, Jindra, Pavel, Afanasyev, Boris, Wagner, Eva, Chalandon, Yves, Henseler, Anja, Schoenland, Stefan, Kroeger, Nicolaus, and Schetelig, Johannes

47. Comparison of magnetic resonance imaging and (67)gallium scintigraphy in the evaluation of posttherapeutic residual mediastinal mass in the patients with Hodgkin's lymphoma.

Author

Herman M, Paucek B, Raida L, Myslivecek M, and Zapletalová J

Subjects
Adult, Cohort Studies, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Hodgkin Disease pathology, Humans, Male, Mediastinal Neoplasms pathology, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm, Residual pathology, Predictive Value of Tests, Sensitivity and Specificity, Treatment Outcome, Whole Body Imaging, Gallium Radioisotopes, Hodgkin Disease therapy, Magnetic Resonance Imaging methods, Mediastinal Neoplasms therapy, Neoadjuvant Therapy, Radiopharmaceuticals, Tomography, Emission-Computed, Single-Photon methods
Abstract

Introduction: Detection of residual disease following the completion of primary treatment in Hodgkin's lymphoma (HL) patients diagnosed with mediastinal tumor mass has an exceptional importance in the assessment of therapeutic response. Magnetic resonance imaging (MRI) and (67)gallium ((67)Ga) scintigraphy can be used to identify active tumor tissue in the mediastinal residuum., Aims: To evaluate: the accuracy of MRI and (67)Ga scintigraphy in the prediction of clinical HL relapse/progression; congruence of findings and the probability of mediastinal disease relapse/progression regarding to the detection of active/inactive tissue by both imaging methods., Materials and Methods: Thirty HL patients with abnormal mediastinal tissue following the completion of primary treatment were examined by MRI and (67)Ga scintigraphy. Positive findings were: high signal intensity on unenhanced T2-weighted images on MRI and the abnormal accumulation of gallium on scintigraphy or SPECT. These findings were compared with the clinical follow-up., Results: Sensitivity, specificity, accuracy, positive and negative predictive values were: 75.0%, 96.2%, 93.3%, 75.0%, 96.2% in MRI and 50.0%, 88.5%, 83.3%, 40.0%, 92.0% in (67)Ga scintigraphy. Discrepant results concerning the mediastinal tissue activity were found in 3 of 30 patients (10%). No statistically significant differences were found between both imaging methods in sensitivity, specificity and accuracy. Estimated 2-years progression free survival (PFS) for patients without and with active residual mediastinal tissue by MRI was 96% and 25% (p=0.0001), respectively. The probability of 2-years PFS in the cases with negative and positive findings on (67)Ga scintigraphy was 92% and 60% (p=0.026), respectively., Conclusion: Although MRI showed better results than (67)Ga scintigraphy in the assessment of residual mediastinal tissue activity in HL patients after primary treatment, the difference between these methods was not statistically significant. Both methods could be included in the standard restaging protocol.

Published
2007
Full Text
View/download PDF

48. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial.

Author

Faber E, Pytlík R, Slabý J, Zapletalová J, Kozák T, Raida L, Papajík T, Zikesová E, Maresová I, Hamouzová M, Indrák K, and Trnený M

Subjects
Adult, Female, Filgrastim, Humans, Male, Middle Aged, Neutrophils drug effects, Neutrophils metabolism, Placebos, Prospective Studies, Recombinant Proteins, Time Factors, Granulocyte Colony-Stimulating Factor administration & dosage, Granulocyte Colony-Stimulating Factor therapeutic use, Lymphoma drug therapy, Peripheral Blood Stem Cell Transplantation methods, Transplantation, Autologous methods
Abstract

Objectives: To explore the safety and effectiveness of the individually determined application granulocyte-colony stimulating factor (G-CSF) after autologous peripheral blood stem cell transplantation (ASCT)., Methods: The administration of G-CSF from day +5 (arm A) was compared in a randomised, controlled trial with delayed, individually determined administration (G-CSF started when WBC >or= 0.5 x 10(9)/L and ANC >or= 0.1 x 10(9)/L or at day +10; arm B), and with placebo (arm C)., Results: One hundred and six patients, median age 45 (range 21-64), all with malignant lymphoma treated with BEAM chemotherapy were analysed. A significant difference in the time to neutrophil engraftment and in the duration of neutropenia <0.5 x 10(9)/L and <1.0 x 10(9)/L was observed between the arms (P = 0.04-<0.0001) with a 1-d prolongation of the median durations in arm B in comparison with arm A but a 2-4-d prolongation in the placebo arm C in comparison with arm B. The median number and range of days to neutrophil engraftment >0.5 x 10(9)/L after graft re-infusion was 10 (9-14) in arm A; 11 (9-19) in arm B; and 14 (10-30) in arm C (P < 0.0001). Engraftment of platelets to >20 x 10(9)/L and >50 x 10(9)/L was significantly delayed in the arms using G-CSF in comparison with placebo (P = 0.04-0.002) without any increase in bleeding or in transfusion requirement. There was no difference in the incidence and duration of transplant-related complications and their treatment between the arms., Conclusions: Our study has confirmed the safety of individually determined administration of G-CSF. The optimal timing of G-CSF application after ASCT in patients with good-quality grafts is shortly before expected spontaneous engraftment.

Published
2006
Full Text
View/download PDF

49. Sources and pathways of spread of vancomycin-resistant enterococci in hemato-oncological patients.

Author

Vagnerova I, Sauer P, Kolar M, Slepickova S, Hubacek J, Faber E, Raida L, and Papajik T

Subjects
Cross Infection transmission, Drug Resistance, Bacterial, Enterococcus classification, Humans, Teicoplanin pharmacology, Cross Infection microbiology, Enterococcus drug effects, Enterococcus isolation & purification, Gram-Positive Bacterial Infections transmission, Hematologic Neoplasms microbiology, Vancomycin Resistance
Abstract

The presented study aims at analyzing an increasing prevalence of vancomycin-resistant enterococci (VRE) isolated from various kinds of clinical material obtained from patients in the Department of Hemato-oncology (DHO), University Hospital in Olomouc, Czech Republic. Between January 1 and March 31, 2005, enterococci were isolated by standard microbiological procedures using both clinical material obtained from hospitalized patients and samples from the department environment. Resistance to vancomycin and teicoplanin was determined by a standardized microdilution method. Phenotype determination of resistance to vancomycin was verified by PCR detection of vanA and vanB genes. In VanA Enterococcus faecium, macrorestriction analysis was performed by pulsed-field gel electrophoresis. During the monitored period, a total of 128 Enterococcus sp. strains were isolated, of which 38 (30 %) isolates from 22 different patients were determined as VRE. Dominating were Enterococcus faecium VanA (63 %) and Enterococcus casseliflavus VanC (16 %) strains. At the same time, one Enterococcus faecium VanA strain was acquired from a bed-side table used by a patient in whom a similar strain had been isolated repeatedly from various clinical materials including a rectal swab taken in 2004. Based on the macrorestriction analysis of genome DNA in 24 vancomycin-resistant Enterococcus faecium VanA strains isolated from the patients' clinical material, one strain from the bed-side table surface and one strain isolated from stools in 2004, 8 unique restriction profiles with similarity ranging from 90 % to 100 % were identified, which could be classified into 3 clonal types. Thus, we can assume not only the endogenous origin of the VRE in hemato-oncological patients and their potential selection caused by therapy with broad-spectrum antibiotics but also the ability of the strains to survive in a hospital setting and, subsequently, to be spread clonally by various vectors.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results